Introduction PEP to HIV is a course of antiretroviral drugs administered within 72 hrs after events with high risk of exposure to HIV aiming to reduce the odds of established infection. We evaluated the putative HIV exposed individuals referred to the Medical university of Vienna general hospital and indicated for PEP in years 2008–2012.

Methodology and Results We have analysed the data from 450 individuals. Our data demonstrates that:

• 44.1% are females,

• indication type: unprotected homosexual contact [28.5%, from which 45% of source patients (SPs) were HIV positive], needlestick injuries (22.8%, 37.5% HIV positive SPs), unprotected heterosexual contact (21.4%, 20% HIV positive SPs), occupational exposure (12.8%, 100% HIV positive SPs), rape (11.4%) and needle exchange by IVDUs (2.8%) where HIV status of SPs were unknown,

• PEP regimens were combination of lopinavir/ritonavir with tenofovir/emtricitabine (79.4%), darunavir/ritonavir with tenofovir/emtricitabine (10.1%) or lopinavir/ritonavir with lamivudine/zidovudine (10.5%),

• 58.8% of individuals tolerated the PEP without any adverse events, 35.3% had minor adverse events (nausea, fatigue, diarrhoea, abdominal discomfort or slight elevation of pancreatic enzymes) and in 5.8% PEP was modified or discontinued (severe adverse events: strong diarrhoea, abdominal pain and vomiting or significant elevation of liver function parameters),

• 77.1% of patients missed at least one of their follow-up visits planned at 1, 3 and 6 months after PEP start, and

• no case of seroconversion was observed.

Conclusion Approximately equal numbers of sexes seek counselling service for PEP. Most prevalent types of exposure include high risk sexual contact and needlestick injuries. Lopinavir/ritonavir with tenofovir/emtricitabine combination seems to be a well tolerated and effective therapy.